Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 14, 2021; 27(46): 7943-7955
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.7943
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.7943
Figure 1 Coronavirus disease 2019 induced inflammatory bowel diseases mechanism.
ADAM17: A disintegrin and metalloprotease domain 17; ACE2: Angiotensin-converting enzyme 2; TMPRSS2: Transmembrane serine protease 2; SARS-Cov-2: Severe acute respiratory syndrome coronavirus 2; GCSF: Granulocyte colony-stimulating factor; IP-10: Interferon gamma-induced protein 10; MCP1: Monocyte chemoattractant protein 1; MIP1-α: Macrophage inflammatory proteins-α; IBD: Inflammatory bowel diseases.
- Citation: Lashgari NA, Momeni Roudsari N, Momtaz S, Abdolghaffari AH. Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment. World J Gastroenterol 2021; 27(46): 7943-7955
- URL: https://www.wjgnet.com/1007-9327/full/v27/i46/7943.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i46.7943